Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 225

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Variants of Toll-Like Receptor 4 Modify the Efficacy of Statin Therapy and the Risk of Cardiovascular Events

Open access
Boekholdt, S. Matthijs, Agema, Willem R.P., Peters, Ron J.G., Zwinderman, Aeilko H., van der Wall, Ernst E., Reitsma, Pieter H., Kastelein, John J.P., Jukema, J. Wouter · 2003 · Circulation

Abstract

Background— Atherosclerosis is increasingly considered to be a chronic inflammatory process. We examined whether genetic variants of the toll-like receptor 4 (TLR4), which are correlated with impaired innate immunity and with progression of carotid atherosclerosis, are also associated with coronary atherosclerosis and predict the risk of cardiovascular events. Methods and Results— Two polymorphisms of the TLR4 gene (Asp299Gly and Thr399Ile) were determined in 655 men with angiographically documented coronary atherosclerosis. All patients participated in a prospective cholesterol-lowering trial evaluating the effect on coronary artery disease and were randomly assigned to either pravastatin or placebo for 2 years. There were no significant differences between genetically defined subgroups with respect to baseline risk factors, treatment, or in-trial changes of lipid, lipoprotein, or angiographic measurements. Genotype was not associated with progression of atherosclerosis. In the pravastatin group, 299Gly carriers had a lower risk of cardiovascular events during follow-up than noncarriers (2.0% versus 11.5%, P =0.045). Among noncarriers, pravastatin reduced the risk of cardiovascular events from 18.1% to 11.5% ( P =0.03), whereas among 299Gly carriers this risk was strikingly reduced from 29.6% to 2.0% ( P =0.0002, P =0.025 for interaction). Conclusions— Among symptomatic men with documented coronary artery disease, the TLR4 Asp299Gly polymorphism was associated with the risk of cardiovascular events. This variant also modified the efficacy of pravastatin in preventing cardiovascular events, such that carriers of the variant allele had significantly more benefit from pravastatin treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000068311.40161.28

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 225

Metadata

Authors
Boekholdt, S. M., Agema, W. R. P., Peters, R. J. G., Zwinderman, A. H., van der Wall, E. E., Reitsma, P. H., Kastelein, J. J. P., & Jukema, J. W.
Venue
Circulation
Published
2003-05-20
Volume
107
Issue
19
Pages
2416-2421
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2130019417
Cited by
225
References
5
FWCI
26.95
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Variants of Toll-Like Receptor 4 Modify the Efficacy of Statin Therapy and the Risk of Cardiovascular Events. https://app.cochat.ai/papers/10.1161/01.cir.0000068311.40161.28
The paper
Boekholdt, S. M., Agema, W. R. P., Peters, R. J. G., Zwinderman, A. H., van der Wall, E. E., Reitsma, P. H., Kastelein, J. J. P., & Jukema, J. W. (2003). Variants of Toll-Like Receptor 4 Modify the Efficacy of Statin Therapy and the Risk of Cardiovascular Events. Circulation. https://doi.org/10.1161/01.cir.0000068311.40161.28

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.